Indivior Pharmaceuticals, Inc. to acquire Supernus Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. has agreed to acquire Supernus Pharmaceuticals, Inc. in a strategic acquisition within the healthcare sector. Both companies are based in the United States. The transaction was announced on 1 August 2026. The consideration for the deal is structured entirely in shares. No specific monetary value or currency has been disclosed for this transaction. The completion date has not yet been reported.

This move represents a significant consolidation within the US healthcare industry. The deal structure relies on equity rather than cash, aligning the interests of the parties involved through shared ownership. As the transaction remains in review, the finalisation of the merger is pending. The status indicates that regulatory or internal approvals are still being processed. There is no information available regarding the specific strategic rationale or the expected impact on the combined entity’s operations. The absence of a disclosed deal value suggests that the terms may be complex or subject to further negotiation. The transaction is subject to regulatory approval.